Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: African trypanosomiasis therapies - Pfizer/DNDi/SCYNEXIS

Drug Profile

Research programme: African trypanosomiasis therapies - Pfizer/DNDi/SCYNEXIS

Alternative Names: AN-2920; AN-3520; AN-4169; SCYX-1330682; SCYX-1608210; SCYX-6759

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; SCYNEXIS
  • Developer Drugs for Neglected Diseases Initiative Foundation; Pfizer; SCYNEXIS
  • Class Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported African trypanosomiasis

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for research development in African-trypanosomiasis in USA (PO)
  • 23 Nov 2018 Early research for African trypanosomiasis therapies is ongoing in USA (DNDi pipeline, November 2018)
  • 04 Nov 2017 No recent reports of development identified for early research in African trypanosomiasis in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top